KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $125.7 million.

  • Vertex Pharmaceuticals' Interest & Investment Income fell 491.68% to $125.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $497.2 million, marking a year-over-year decrease of 2343.7%. This contributed to the annual value of $598.1 million for FY2024, which is 270.05% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Interest & Investment Income of $125.7 million as of Q3 2025, which was down 491.68% from $122.4 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Interest & Investment Income ranged from a high of $181.2 million in Q1 2024 and a low of $1.1 million during Q2 2021
  • Over the past 5 years, Vertex Pharmaceuticals' median Interest & Investment Income value was $122.4 million (recorded in 2025), while the average stood at $91.1 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Interest & Investment Income plummeted by 8807.25% in 2021 and then surged by 756250.0% in 2023.
  • Vertex Pharmaceuticals' Interest & Investment Income (Quarter) stood at $1.2 million in 2021, then soared by 7066.67% to $86.0 million in 2022, then soared by 108.72% to $179.5 million in 2023, then decreased by 28.58% to $128.2 million in 2024, then dropped by 1.95% to $125.7 million in 2025.
  • Its last three reported values are $125.7 million in Q3 2025, $122.4 million for Q2 2025, and $120.9 million during Q1 2025.